NICE TA386: Ruxolitinib is recommended as an option for treating disease-related splenomegaly or symptoms in adults with myelofibrosis, post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis only in people with intermediate-2 or high-risk disease. (Decision date April 2016)
NICE TA921: Ruxolitinib for treating polycythaemia vera. NHSE commissioned. (Decision date - November 2023)
NICE TA1054 - Ruxolitinib for treating acute graft versus host disease that responds inadequately to corticosteroids in people 12 years and over (Decision date May 2025)
NICE TA1140 - Ruxolitinib cream for treating non-segmental vitiligo in people 12 years and over (Decision date April 2026)
DO NOT PRESCRIBE (DNP):
NICE TA839: For treating acute graft versus host disease refractory to corticosteroids. Terminated appraisal (Decision date - December 2022)
NICE TA840: For treating chronic graft versus host disease refractory to corticosteroids. Terminated appraisal (Decision date - December 2022)
NICE TA1132: (terminated appraisal) Ruxolitinib for treating moderate to severe chronic graft versus host disease after an allogeneic stem cell transplant in people 28 days to 17 years (Decision date March 2026)
NHSE commissioned
Do Not Prescribe (DNP) Drug Classifications
6: Have NICE guidance that recommends they should not be used
Red Drug Classifications
1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
3: Requiring long term on-going monitoring of toxicity by a specialist (either because of difficulty in recognising side effects or high cost of investigations to identify toxicity)
8. NHS England commissioned – to be used in line with NHSE commissioning intentions
